Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Savarirayan

Showing results (1-10 of 186) with videos related to

Pageof 19
Sort By:
Expert Opinion on Therapeutic Targets|May 12, 2022
Emerging drug targets for achondroplasiaRavi Savarirayan
Nature Reviews. Endocrinology|May 13, 2024
Advances in the management of achondroplasiaRavi Savarirayan
American Journal of Medical Genetics. Part A|May 8, 2016
Emerging targeted drug therapies in skeletal dysplasiasPatrick Yap, Ravi Savarirayan
Orphanet Journal of Rare Diseases|February 24, 2009
OsteopetrosisZornitza Stark, Ravi Savarirayan
Expert Opinion on Emerging Drugs|November 11, 2021
Emerging therapies for Achondroplasia: changing the rules of the gameSmitha Kumble, Ravi Savarirayan
The New England Journal of Medicine|June 18, 2025
Oral Infigratinib Therapy in Children with Achondroplasia. ReplyRavi Savarirayan, Daniela Rogoff
Advances in Pediatrics|September 16, 2004
Skeletal dysplasiasRavi Savarirayan, David L Rimoin
Nature Reviews. Endocrinology|May 1, 2025
Reply to 'Ensuring diverse representation and minimizing conflicts of interest in clinical practice guidelines'Ravi Savarirayan, Svein Otto Fredwall
Bone|August 16, 2020
Novel therapeutic approaches for the treatment of achondroplasiaLaurence Legeai-Mallet, Ravi Savarirayan
Journal of Paediatrics and Child Health|September 5, 2017
Successful Use of Enzyme Replacement Therapy in Infantile HypophosphatasiaPeter J Simm, Ravi Savarirayan
Pageof 19

Showing results (1-10 of 186) with videos related to

Sort By:
Pageof 19
Expert Opinion on Therapeutic Targets|May 12, 2022
Emerging drug targets for achondroplasiaRavi Savarirayan
Nature Reviews. Endocrinology|May 13, 2024
Advances in the management of achondroplasiaRavi Savarirayan
American Journal of Medical Genetics. Part A|May 8, 2016
Emerging targeted drug therapies in skeletal dysplasiasPatrick Yap, Ravi Savarirayan
Orphanet Journal of Rare Diseases|February 24, 2009
OsteopetrosisZornitza Stark, Ravi Savarirayan
Expert Opinion on Emerging Drugs|November 11, 2021
Emerging therapies for Achondroplasia: changing the rules of the gameSmitha Kumble, Ravi Savarirayan
The New England Journal of Medicine|June 18, 2025
Oral Infigratinib Therapy in Children with Achondroplasia. ReplyRavi Savarirayan, Daniela Rogoff
Advances in Pediatrics|September 16, 2004
Skeletal dysplasiasRavi Savarirayan, David L Rimoin
Nature Reviews. Endocrinology|May 1, 2025
Reply to 'Ensuring diverse representation and minimizing conflicts of interest in clinical practice guidelines'Ravi Savarirayan, Svein Otto Fredwall
Bone|August 16, 2020
Novel therapeutic approaches for the treatment of achondroplasiaLaurence Legeai-Mallet, Ravi Savarirayan
Journal of Paediatrics and Child Health|September 5, 2017
Successful Use of Enzyme Replacement Therapy in Infantile HypophosphatasiaPeter J Simm, Ravi Savarirayan
Pageof 19